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Abstract
Acute decompensated heart failure (ADHF) accounts for more than 1 million hospital admissions annually and is associated with high morbidity and mortality. Decongestion with removal of increased total body sodium and total body water
are goals of treatment. Acute kidney injury (AKI) or chronic kidney disease (CKD) is present in two-thirds of patients with
ADHF. The pathophysiology of ADHF and AKI is bidirectional and synergistic. AKI and CKD complicate the management
of ADHF by decreasing diuretic efficiency and excretion of sodium and water. Among patients hospitalized with ADHF,
hyponatremia is the most common electrolyte abnormality and is classically encountered with volume overload. ADHF
represents an additional therapeutic challenge particularly when oligoanuria is present. Predilution continuous venovenous
hemofiltration with sodium-based osmotherapy can safely increase plasma sodium concentration without deleteriously
increasing total body sodium. We present a detailed methodology that addresses the issue of hypervolemic hyponatremia
in patients with ADHF and AKI.
Keywords Hyponatremia · Acute decompensated heart failure · Osmotherapy · Ultrafiltration

Introduction
Acute decompensated heart failure (ADHF) accounts for
greater than 1 million hospital admissions annually [1]. Currently in the USA, 5.7 million patients have HF that is responsible for an estimated expenditure of $37.2 billion USD. The
prevalence of HF is projected to be 8 million persons by 2030, a
46% increase [2]. Fluid congestion now accounts for more than
90% of hospital admissions for ADHF [3]. Persistent congestion is present in 40% of ADHF patients at discharge [4] and
leads to a major proportion of rehospitalizations [5]. Therefore,
decongestion is the principal treatment goal for ADHF [6]. The
foremost reason for fluid accumulation in patients with ADHF
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is persistent renal sodium and water retention. Because renal
water reabsorption is disproportionately greater than sodium
reabsorption in many ADHF patients, hyponatremia occurs
and is a poor prognostic factor [7]. However, excessive sodium
retention is the reason for congestion, and reduction of total
body sodium (TBNa) is an obligate component of HF therapy.
This review provides a pathophysiological cardiorenal outline of oligo-anuric ADHF complicated by hyponatremia and
describes a specific treatment model that utilizes continuous
renal replacement therapy.

Hyponatremia
Hyponatremia is the most common electrolyte disorder in
hospitalized patients, occurring in 15–30% of cases [8].
Acute hyponatremia is defined as a plasma sodium concentration (PNa) < 130 mEq/L that transpires within 48 h.
Chronic hyponatremia is defined as P Na < 130 mEq/L
for > 48 h or at presentation for care. Hyponatremia is present in up to 7% of patients in ambulatory settings and is
discovered in nearly 23% of all patients presenting to emergency departments [9]. Among outpatients with HF, the
prevalence of hyponatremia is 17% [10]. In patients admitted for ADHF, hyponatremia, defined as PNa < 135 mEq/L, is
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the most common electrolyte abnormality and is frequently
accompanied by volume overload [11, 12]. Depending on
the rapidity and magnitude of change of P
 Na, clinical features
of hyponatremia may range from generalized fatigue, falls
with potential fractures, and altered mentation and cognitive
dysfunction [13].
In the meta-analysis by Wang et al. that assessed patients
with ADHF, the correction of hyponatremia [14] during
hospital admission was associated with lower cardiovascular mortality compared to patients who experienced no or
minimal improvement of hyponatremia. The improvement of
hyponatremia in ADHF patients was associated with reductions in short-term and long-term all-cause mortality [14] and
hospital readmission [15]. In a study of HF patients by Madan
et al. that had a median follow-up of 610 days, a positive correlation between increased P
 Na and survival was observed.
[16]. Unfortunately, hyponatremia is corrected in only 19% of
ADHF patients by the time of hospital discharge, even after
the application of traditional therapeutic management strategies, including fluid restriction, diuretics, and/or saline administration. [17]. In summary, hyponatremia in ADHF patients is
an easily identifiable and modifiable factor, and its correction
with decongestion is recommended and salutary.

Renal function and ADHF
The kidneys are frequently affected by ADHF, and concomitant acute kidney injury (AKI) or chronic kidney disease
(CKD) is present in 67% of patients [18]. Moderate CKD
with glomerular filtration rates (GFRs) of 30–59 mL/min
per 1.73 m2 was documented in 43.5% of patients hospitalized with ADHF and in 13% of patients with severe CKD
had GFRs of 15–29 mL/min per 1.73 m2. Kidney failure
defined by GFR <15 mL/min per 1.73 m2 developed in 7%
of patients [18]. Concurrent AKI and CKD at admission
or during hospitalization with ADHF is associated with a
worse prognosis [18–21]. Healthy kidneys have a tremendous capacity to excrete water, up to 15 L daily, and water
retention and hyponatremia are infrequent findings until the
GFR is quite depressed. Even at a GFR of 10 mL/min per
1.73 m2, a normal amount of water ingestion will not provoke hyponatremia [22].
Hyponatremia in heart failure patients is mediated by an
exaggerated neurohormonal axis that tightly regulates TBNa
and total body water (TBW) in the normal physiologic state.
Derangements in atriorenal reflexes, the sympathetic nervous system (SNS), the renin-angiotensin-aldosterone system
(RAAS), glomerular filtration, tubular flow, and nonosmotic
arginine vasopressin (AVP) release, collectively result in disproportionate renal reabsorption of salt and water producing
hypervolemic hyponatremia.
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In the normal heart, atrial natriuretic peptide is secreted
in response to increased atrial stretch and high systemic
blood pressure. These stimuli enhance glomerular filtration and augment renal excretion of sodium and water.
With depression of effective arterial blood volume
(EABV) during ADHF, SNS overstimulation from highpressure baroreceptors amplify inotropic and chronotropic
effects to maintain circulatory hemodynamics and perfusion at systemic and renal levels [23]. SNS hyperactivity
potentiates release of renin and activates the RAAS, with
consequent upregulation of sodium-hydrogen exchanger in
proximal tubule cells [24]. The net effect of this cascade
is increased filtration fraction in conjunction with sodium
and water retention at the proximal tubular level, mediated
by angiotensin II (AngII) [25, 26] and aldosterone. In addition, Ang II activates the thirst center and increases AVP
release, thereby promoting water retention in the distal
nephron.
Under normal conditions, AVP release increases linearly in response to increasing plasma tonicity, [27, 28]
with subsequent rapid degradation by liver and kidney. In
HF patients, elevated AVP concentrations stem from nonosmotic release attributable to decreased EABV sensed by
arterial baroreceptors, increased Ang II plasma concentrations, augmented alpha-2 adrenergic receptor stimulation, and decreased hormone degradation from hepatic and
renal dysfunction [29–31]. AVP signaling via the vasopressin type 2 receptor (V2R) upregulates aquaporin-2
channel expression in the medullary collecting duct and
increases water reabsorption [32]. Increased circulating
AVP also activates V1a receptors in the liver and vasa
recta, respectively, increasing hepatic urea production and
urea absorption in the medullary collecting duct which
enhances the interstitial corticomedullary osmotic gradient
[33]. The summative consequences of the hydro-osmotic
effect of AVP in the collecting duct are greater water reabsorption devoid of electrolyte with reduced tubular flow
and reduced urine volume.
Free water excretion is dependent on the tubular function of distal and collecting tubules, which are low waterand high sodium-permeable segments [34]. Decreased cardiac output results in reduced renal blood flow and GFR
which decreases renal tubular flow, with less sodium reabsorption and water excretion. [35, 36]. Decreased blood
flow within the vasa recta further enhances water absorption. Elevated central venous pressures from HF elevate
right-sided cardiac pressures and renal vein pressures. The
consequences of the latter are reduction of the transrenal
pressure gradient and renal congestion. The heightened
renovascular resistance decreases renal blood flow and the
compensatory increase in filtration fraction resulting in
decreased GFR.
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In summary, hyponatremia in patients with ADHF
is promoted by maladaptive responses that eventually
worsen renal function, with disproportional renal sodium
and water reabsorption. Decreased free water excretion
occurs despite increased TBW and TBNa, the clinical consequences of which are pulmonary congestion and peripheral edema with hypotonic, hypervolemic hyponatremia.

Treatment of hyponatremia
The treatment of hyponatremia can be categorized as
reduction of access to water, promotion of urinary water
excretion, and supraphysiological addition of sodium to
the plasma compartment. Oral fluid restriction is classically limited to 1000–1500 mL of total fluids per day.
Adherence to this regimen is practically difficult. Fluid
restriction generally results in a modest P
 Na increase of
2 mEq/L or less per 24 h. Thus, diuretic treatment that
targets the diluting segment of the nephron is usually
necessary.
In the thick ascending limb of Henle’s loop, the site of
the sodium–potassium-chloride cotransporter, loop agents
increase urinary electrolyte-free water loss by disrupting
maximization of the corticomedullary gradient via inhibition of the cotransporter. Urine electrolyte-free water is
the portion of urine devoid of sodium and potassium ions
but contains urea. The net result of loop diuresis is greater
loss of electrolyte-free water. High dose loop diuretics are
required for patients with underlying kidney disease because
its efficacy is limited by decreased GFR and the induction of
diuretic resistance during long-term treatment [37].
V2R antagonists such as conivaptan and tolvaptan also
increase free water excretion. By interrupting the lumento-plasma transit of urea and water at the collecting duct,
these agents produce hypotonic urine. V2R antagonists
facilitate correction of hyponatremia by reducing the
denominator of the Edelman equation. However, despite
increasing P Na , agents have minimal impact on TBNa
attributable to their locus of action (i.e., minimal sodium
reabsorption occurs in the inner medullary collecting
duct). These “aquaretic” agents have not been proven salutary in ADHF or for patients with chronic HF [38, 39].
Hypertonic saline as solutions of 2% to 23.4% saline are
administered to increase P
 Na. As a corrective measure for
hyponatremia, hypertonic saline represents a double-edged
sword. Salutary PNa elevation proceeds at the expense of
increasing TBNa, which may aggravate cardiopulmonary
congestion. Nonetheless, hypertonic saline combined with
high-dose diuretics has been advocated for refractory cases
of ADHF with severe symptomatic and very low or rapidly
declining PNa [40, 41]. If this combination therapy is used,

careful monitoring and accounting of sodium and water
inputs and outputs is mandatory to prevent worsening congestion from sodium-loading. If the diuretic response of
congested, hypervolemic patients is inadequate, mechanical ultrafiltration is advised. The current American College of Cardiology guidelines recommend ultrafiltration in
patients who have obvious fluid overload or patients who
do not respond adequately to diuretics [6].
In the following review, we outline a therapeutic solution for hyponatremic patients who have ADHF and limited urine output—sodium-based osmotherapy (SBO). We
model predilution continuous venovenous hemofiltration
(CVVH) as the therapeutic vehicle that increases P
 Na without increasing TBNa.

Osmolality and tonicity
Osmolality is defined as the number of milliosmoles of
solute per kilogram of solvent, and the solvent is water
for biological systems. Optimal cell function and cell volume homeostasis occurs at plasma osmolality of 275 to
290 mOsm/kg H2O, with no osmotic gradient between the
intracellular and extracellular milieus [36, 42]. Tonicity, or
effective osmolality, is the concentration of effective osmoles
that are impermeant to cell membranes and that displace
water, thus regulating cell volume. Because sodium with
its accompanying anions is the most abundant extracellular
osmole, sodium represents the major determinant of plasma
tonicity. However, urea, permeates cells readily and is not
an effective osmole at osmotic equilibrium. With plasma as
the referent solution, hypotonicity indicates that water will
flow into cells, whereas hypertonicity implies cell shrinkage.
An abrupt reduction in plasma tonicity from hyponatremia
is acutely reconciled by egress of electrolytes from cells.
Chronic hypotonicity induces a reduction of intracellular
osmolyte concentration that is required to preserve cell volume to prevent untoward cell volume expansion, e.g., cerebral edema [43].

Sodium and total body water
The ubiquitous, electrogenic Na-K-ATPase maintains a high
extracellular sodium concentration and a high intracellular
potassium concentration to preserve cellular osmotic equilibrium. This concept is delineated by Eqs. 1 and 2 in which
PNa is the ratio of the sum of exchangeable TBNa (TBNae)
and potassium (TBKe) ions to TBW [44]. TBW is determined from anthropometric data as the urea space [45].
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PNa = (1.11 ×

TBNae + TBK e
) − 25.6
TBW

(1)

The modified Edelman equation is commonly simplified
as follows:

PNa =

TBNae + TBK e
TBW

(2)

As exchangeable potassium is quantitatively minor compared to exchangeable sodium, Eq. 2 is further simplified to
Eq. 3 for general clinical application.

PNa =

TBNae
TBW

(3)

And

TBNae = TBW × PNa

(4)

The hyponatremia that occurs during ADHF is hypervolemic and attributable to the greater increase of the denominator (TBW) relative to the numerator TBNae.

Exchangeable and non‑exchangeable
sodium
TBNa is distributed within several compartments: 65%
plasma, 5–10% intracellular fluid, and 25% bone and interstitial tissues. In healthy individuals, fluid accumulation in
tissues is opposed by a reduction of interstitial compliance
that exerts a hydrostatic pressure that promotes return of
fluid into the systemic circulation via lymphatic networks
[46, 47]. Sodium is also segregated from TBNa by interstitial glycosaminoglycans, particularly in skin and muscle, and
escapes osmotic regulation by pituitary osmoreceptors and
kidney [48]. This minimally exchangeable sodium pool may
be important in HF and CKD [49]. Accordingly in ADHF,
sodium radiolabeling studies have demonstrated sodium
accrual without weight (water) gain [50]. 23Na-MRI has also
demonstrated sodium accumulation in muscle, brain, and
skin. Conversely, in patients with hyperaldosteronism, there
is 23Na-MRI confirmation of this non-exchangeable ion pool
[51], which can be mobilized without weight loss. This pool
of non-exchangeable sodium can be mobilized by diuretic
therapy [52] or ultrafiltration [53]. Essentially, these sequestered sodium stores represent a reservoir that contributes to
persistently high TBNa and congestion.
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Myocardial contractility in hyponatremia
Hyponatremia adversely affects myocyte function and contractility by multiple mechanisms. The sodium-calcium
exchanger and Na-K-ATPase modulate calcium entry into
cardiomyocytes which regulates myocardial contractility
[54]. Plasma concentrations of sodium, potassium, calcium, and magnesium regulate RUNX1 gene transcription
that accelerates proliferation and differentiation of injured
myocytes. Hyponatremia may impair RUNX1-mediated
cardiomyocyte remodeling following myocardial infarction [55]. L-type calcium channels are responsible for the
release of intracellular calcium from the sarcoplasmic reticulum, with myocyte activation and contraction. L-channel
activity is downregulated by the rapid induction of acute
hyponatremia with reduced cardiomyocyte contractility
[56, 57] However, such short-term studies do not reflect the
time course during which hyponatremia typically develops in patients with ADHF. Moreover, the contribution of
hyponatremia to ADHF has not been quantified rigorously.
Nonetheless, severe hyponatremia remains a potential risk
factor for impaired cardiac contractility in ADHF.

Hyponatremia‑induced arrhythmia
PNa is a major determinant of the cardiomyocyte resting
membrane potential. Since ventricular arrhythmia results
from disruption of cardiomyocyte depolarization or repolarization and/or action potential conduction, hyponatremia
is a potential risk factor for arrhythmogenesis. Clinically, the
frequency and complexity of ventricular extrasystoles are
associated with worsening hyponatremia [56]. Voltage-gated
sodium channels and gap junction proteins retard action
potential conduction velocity and may contribute to arrhythmia. Gain-of-function mutations that prolong activation of
fast sodium channels increase ventricular depolarization and
arrhythmias, e.g., long QT syndrome. In Brugada syndrome,
loss-of-function mutations of slow and fast sodium channels
produce sodium channel inactivation and sustained repolarization, triggering ventricular arrhythmias [56, 58]. Atrial
arrhythmias such as atrial fibrillation occur more frequently
in patients with hyponatremia who present to emergency
departments [59] and who undergo open heart surgery [60].
Hyponatremia in heart failure patients with reduced ejection fraction has been independently associated with atrial
fibrillation. [61]. Cases of complete heart block in patients
with hyponatremia and without cardiac disease have shown
improvement after correction of hyponatremia [62].
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Osmotherapy for hyponatremia
in hypervolemic heart failure
Most hyponatremic ADHF patients have chronic hyponatremia. Slow correction of P
 Na is recommended for these
patients to prevent rapid fluctuation of osmotic gradients
and attenuate the risk of iatrogenic neurologic sequelae,
e.g., osmotic demyelination syndrome (ODS), which results
from overly rapid correction of hyponatremia [43]. Current
consensus guidelines recommend correction of the chronic
hyponatremic state by 6–8 mEq/L per 24 h [63]. Individuals with a history of severe alcohol abuse, particularly
those with complicating features of hypokalemia, malnutrition, low TBW, and liver disease, are at increased risk for
ODS. ODS has occurred in older HF patients with a history
of alcohol abuse who manifested severe hyponatremia [64].
Several modalities of renal replacement therapy, including hemodialysis, sustained low-efficiency dialysis (SLED),
and CVVH a form, of continuous renal replacement therapy
(CRRT), have been employed to correct hyponatremia and
treat hypervolemic ADHF patients with oligo-anuric AKI
[65]. The constellation of hypervolemia, AKI with oligoanuria, and hyponatremia poses a therapeutic challenge,
especially in hemodialysis. In this circumstance, rapid reduction of urea can be complicated by neurological symptoms,

Fig. 1  Sodium-based osmotherapy with predilution continuous
venovenous hemofiltration (CVVH) setup. A blood pump (P) delivers plasma at sodium concentration P
 Na at rate Q
 P and replacement
fluid (RF) at flow rate QRF with a sodium concentration (NaRF) into
the hemofilter (F). The effluent flow rate (QE) is the sum of Q
 RF and

e.g., dialysis disequilibrium syndrome [66] from generation
of an osmotic gradient that favors rapid ingress of water
into the brain.
Mitigating the risk of brain injury during correction of
hyponatremia by CRRT involves strategic flow rate adjustments of plasma and replacement fluid [67, 68] and monitoring of net sodium mass balance. Compared to hemodialysis,
continuous therapy affords gradual correction of PNa and
decongestive treatment by ultrafiltration. We provide a readily available and implementable solution for patients with
ADHF, hyponatremia, and kidney failure.

CVVH setup and implementation
We utilize predilution CVVH because of its simplicity and
modeling characteristics. CVVH utilizes an extracorporeal
circuit that maintains a closed loop between the patient’s
blood and a hemofilter (Fig. 1) [68]. A blood pump regulates plasma flow ( QP) into a conventional hemofilter (F).
A sodium-based replacement fluid (RF) of sodium concentration NaRF is advected into the fluid flow prehemofilter.
The ultrafiltration flow rate ( Q UF) is determined by the
operator such as a nephrologist or intensive care specialist.
Commercial RF solutions are supplied at sodium concentrations of 130 and 140 mEq/L and may be customized to

the ultrafiltration flow rate ( QUF). The plasma flow rate exiting the filter that is returned to the patient ( →) is the difference between Q
P
and QUF. PNa is gradually increased by the addition of RF that has a
greater sodium concentration (NaRF) than PNa
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specific sodium concentrations ( NaRF) by the addition or
subtraction of water or hypertonic saline [68]. PNa is raised
by the relatively hypertonic RF while TBW is reduced by
ultrafiltration. Therefore, the numerator of the Edelman
Equation is increased while the denominator is decreased,
thereby raising P
 Na. During SBO, P
 Na is incrementally elevated toward the target PNa, avoiding dangerous and rapid
elevations of cerebral and cardiac tonicity.

SBO therapy will have a treatment time tx = 24 h = 1440 min.
Urea kinetic modeling defines BUN at any treatment time (t)
as BUN(t) (Eq. 8).
−

BUN(t) = BUN 0 ⋅ e

KUrea ⋅t
V0

The BUN at end treatment at time tx can be calculated.
Here, tx is 1440 min.

BUN(1440) = 92 ⋅ e−

Case

(8)

26⋅1440
42000

= 37.7mg∕dL

(9)

Once KUrea is established, SBO treatment parameters are
specified. Since urea (mol wt, 60 g/mol) and sodium (mol
wt, 23 g/mol) freely pass through the filter membrane, the
dialysance of sodium (DNa) is essentially equivalent to urea
clearance or KUrea [74, 75]. DNa is subsequently defined by
Eq. 10.

We present a hypothetical, illustrative case of a 54-year-old
man with HF and reduced ejection fraction. He has dyspnea,
progressive, bilateral lower extremity swelling, and has gained
6 kg in 1 week. The admission height and weight are 170 cm
and 78 kg, respectively. Admission laboratory data are plasma
sodium 118 mEq/L, potassium 5.2 mEq/L, blood urea nitrogen
92 mg/dL, creatinine 6.4 mg/dL (baseline, 3.0 mg/dL), and
hematocrit (Hct) 0.30. No urogenital obstruction was identified
by ultrasonography, and a furosemide stress test was negative
(urine output < 200 mL 2 h after 1.5 mg/kg intravenous furosemide) [69]. The TBW at admission (V0) is calculated using
the patient’s sex, height, age, and weight by the Watson volume formula (Eqs. 4 and 5) and yields V0 = 42L = 42,000 mL.

)
(
QP
(BUN)DNa = KUrea = (
) ⋅ QRF + QUF = 26mL∕min
QP + QRF

TBW(male) = 2.447 − (0.09156 × age)

QP = QB ⋅ (1 − Hct) = 200mL∕min ⋅ (1 − 0.30) = 140mL∕min
(11)

+ (0.1074 × height) + (0.3362 × weight)

(5)

TBW(female) = −2.097 + (0.1069 × height) + (0.2466 × weight)

(6)

The proposed treatment is predilution CVVH-SBO for HF
with oligoanuric AKI and poor response to diuretics [6, 68,
70]. Therapy is planned by a stepwise mathematical approach
and based on urea- and sodium-based kinetic modeling [71].
First, urea clearance (KUrea) is estimated assuming a minimal,
recommended effluent clearance of 20 mL/kg/h per Eq. 7 [72,
73] (Table 1).

KUrea =(78kg ⋅ 20mL∕kg∕h)∕60 min ∕h = 26mL∕min

(7)

(10)

QRF is the predilution RF flow rate; QUF is the ultrafiltration rate; the extracorporeal circuit plasma flow rate, Q
 P, is
derived from the blood flow rate QB and hematocrit (Hct)
per Eq. 11 (Fig. 1):

SBO modeling may be used to increase or decrease
the PNa. The value of the initial plasm sodium (NaPre) is
118 mEq/L. A safe and desired change of P
 Na (ΔNa)
is + 6 mEq/L, and this value defines the post-treatment
plasma sodium (NaPost) per Eq. 12.

NaPost = NaPre + ΔNa = 118 + 6 = 124mEq∕L

(12)

Using this method, any feasible value for Q
 UF can be used
during treatment. For this case, the Q
 UF that achieves “zero”
sodium balance is chosen. TBNa0 and TBNatx are, respectively, pre- and post-treatment TBNa levels (mEq). If QUF
is > 0 mL/min, the volume at end-treatment is ( V0 − QUF ⋅
tx). Equation 13 defines T
 BNa0 and Eq. 14 defines TBNatx.

Table 1  Proposed mechanisms of arrythmia due to hyponatremia
Ventricular arrhythmia

Atrial fibrillation

Disrupts cellular depolarization and repolarization
Increases ventricular electrical activity
Decreases conduction velocity

Blocks inhibitory function of AV node accessory pathway
Prevents depolarization phase of AV node
Decreased NCX activity increases intracellular calcium,
diastolic PV distension, and PV burst firing

Prolongs activation and deactivation of action potential channels
AV atrioventricular, NCX sodium-calcium exchanger, PV pulmonary vein
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TBNa0 = NaPre ⋅ V0

(13)

TBNatx = NaPost ⋅ (V0 − QUF ⋅ tx)

(14)

At zero sodium balance, T BNa tx − T BNa 0 = 0 mEq
(Eq. 15).
)
(
) (
NaPost ⋅ V0 − QUF ⋅ tx − NaPre ⋅ V0 = 0
(15)
Equation 15 can be solved for the ultrafiltration rate that
achieves zero sodium balance (Eq. 16).
(
)
V0 ⋅ NaPost − NaPre
42000 ⋅ (124 − 118)
QUF =
=
NaPost ⋅ tx
124 ⋅ 1440
(16)
= 1.41mL∕min = 2.03L∕24h
The value of the replacement fluid flow rate is calculated by solving Eq. 10 for QRF, which yields Eq. 17.
(
)
QP ⋅ QUF − DNa
140 ⋅ (1.41 − 26)
QRF =
=
= 30.2mL∕min
(
)
26 − 140
DNa − QP
(17)
PNa at any time (t) is defined as PNa(t) and calculated
by Eq. 18.
(
)
D ⋅t
(
)
− VNa
0
PNa (t) = NaPre + NaRF − NaPre ⋅ 1 − e
(18)

The proportional change of PNa from beginning to end
of treatment is the sodium adjustment ratio (NaAR) and
provided by Eq. 19.
−

NaAR = 1 − e

DNa ⋅t
V0

= 1 − e−

26⋅1440
42000

= 0.59

(19)

Na Post, which equals P Na(1440) at treatment-end is
determined by Eq. 20.
)
(
NaPost = NaPre + NaRF − NaPre ⋅ NaAR
(20)
Equation 20 can now be solved for the required value
of replacement fluid sodium concentration NaRF Eq. 21.

NaPost − NaPre ⋅ (1 − NaAR)
NaAR
124 − 118 ⋅ (1 − 0.59)
= 128.2mEq∕L
=
0.590

NaRF =

(21)

Substituting NaPre, NaRF, V0, and DNa into Eq. 18 and
solving for the final plasma sodium at the end of the treatment is determined in Eq. 22.
(
)
26⋅1440
PNa (1440) = 118 + (128.17 − 118) ⋅ 1 − e− 42000 = 124 mEq∕L

(22)
The change in TBNa (ΔTBNa) can be defined as a continuous function of time (t) using the equation for PNa(t).
The value of ΔTBNa(t) is the product of the current P
 Na(t)
and volume (V0 − QUF t) (Eq. 23).

Fig. 2  Sodium-based osmotherapy modeling calculations for continuous venovenous hemofiltration show that the plasma sodium concentration
increases at the same rate regardless of ultrafiltation rate ( QUF, L/24h)
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(
)
ΔTBNa(t) = PNa (t) ⋅ V0 − QUF ⋅ t − NaPre ⋅ V0

(23)

In Eq. 23, the zero change in TBNa is calculated per
Eq. 24.
)
(
1.411
⋅ 1440 − 118 ⋅ 42 = 0mEq
ΔTBNa(1440) = 124 ⋅ 42 −
1000

(24)

Figure 2 illustrates that when DNa and N
 aRF are adjusted
for a specified QUF, the change in PNa(t) over 24 h is equal
at final volumes, ranging from 42 L at Q
 UF of 0 L/24 h to
38 L at Q
 UF of 4 L/24 h. Figure 3 shows the corresponding
changes in ΔTBNa(t) for the same range of Q
 UF values 0 to
4 L/24 h. For QUF of 0 L/24 h, TBNa increases by 252 mEq
and for QUF 4 L/24 h, TBNa decreases by 244 mEq by the
end of treatment. The QUF (1.41 mL/min, 2.03 L/24 h) that
achieves zero sodium balance demonstrates a maximal
ΔTBNa(t) that is 32 mEq greater than the initial TBNa of
4956 mEq. ΔTBNa(t) returns to 0 mEq after 24 h, sidestepping the intrinsic sodium accrual that attends a positive
change of PNa. SBO modeling parameters and calculations
for the first 24 h are summarized in Table 2.
Since P Na should be increased by no more than
6–8 mEq/L in 24 h, computations must be repeated every
24 h and CVVH parameters changed accordingly, while PNa

Fig. 3  The change in total body sodium (ΔTBNa) varies with ultrafiltration rate 
(QUF). For 
QUF = 0, ΔTBNa is continuously positive because sodium is added to the TBW without removal. For
QUF = 2.032 L/24 h, calculated to achieve zero sodium balance,
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is monitored at 2- to 4-h intervals. To achieve the new target PNa of 130 mEq/L, treatment parameters must be calculate using a reduced body water (V0 – QUF · tx). Modeling
parameters for the second 24-h time period are provided
in Table 3. Calculations in Table 3 are identical to those in
Table 2 except for the first and second rows.
For the second SBO modeling, a lesser URR value of 0.4
is chosen, and urea removal is reduced from 59 to 40% for
the second treatment. KUrea is next determined from the value
of URR using the formula in Table 3 (line 2, column 2) and
reduced from 26 to 14.37 mL/min. Using the reduced value of
KUrea, the new value of B
 UN0 is 37.7 mg/dL. BUNtx from the
previous treatment is reduced to 23.2 mg/dL (Table 3, line 3).
Since DNa is equivalent to KUrea, which equals 14.19 mL/min,
SBO modeling for the second treatment is changed. Now, the
QUF that achieves zero sodium balance declines from 1.411 to
1.282 mL/min and QRF decreases from 30.2 to 14.37 mL/min.
The SBO modeling equations compensate for the decrease in
 aRF from 128.2 to 139 mEq/L. AccordDNa by increasing N
ingly, the sodium concentration gradient between plasma and
replacement fluid must increase from 10.2 to 15 mEq/L. At
the end of the second treatment, P
 Na equals 130 mEq/L and
TBW is 38.2 L. The final computed TBNa of 4960 mEq is
essentially equal to the TBNa of 4956 mEq at the start of

plasma sodium concentration increases to 124 mEq/L without
increasing TBNa. For QUF > 2.032 L/24 h, ΔTBNa is negative and
sodium loss occurs
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Table 2  CVVH parameters during a 24-h treatment
Parameter

Equation

Calculation

Value

Urea clearance (KUrea. mL/min) calculated from patient weight at
20 mL/kg/h
Urea reduction ratio (URR) (percent as a fraction)

Weight(kg)×20ml∕kg∕h
60min∕h

78(kg)×20ml∕kg∕h
60min∕h

26.0 mL/min

BUN Post ( BUNtx, mg/dL)
Final sodium ( NaPost) calculated from initial sodium (NaPre)
Ultrafiltration rate (QUF, mL/min) for zero sodium balance
Plasma flow ( QP, mL/min) calculated from blood flow rate (QB)
Sodium dialysance ( DNa, mL/min)
Replacement fluid flow rate ( QRF, mL/min)
Sodium adjustment ratio (NaAR)
Replacement fluid sodium concentration (NaRF, mL/min)
Sodium concentration gradient (∇Na, mEq/L)
Plasma Na at time (t) during treatment (PNa(t), mEq/L)
Total body sodium (TBNa, mEq)
Change in total body Na at time (t) ΔTBNa(t), milliequivalents
(mEq)

−

1−e

KUrea ∙tx
V0
K
∙tx
− Urea
V

BUN 0 × e
NaPre + 6 mEq/L
V0 ×(NaPost −NaPre )
NaPost ∙tx

QB × (1 – Hct)
DNa = KUrea
QP ×(QUF −DNa )
(DNa −QP )
−

1−e

DNa ∙tx
V0

1 − e−

26×1440
42000

− 26×1440
42000

BUN 0 × e

118 + 6
42000×(124−118)
124×1440

200 × (1 − 0.3)
140×(1.411−26)
26−140

1 − e−

26×1440
42000

0.590
37.7 mg/dL
124 mEq/L
1.411 mL/min
0.0847 L/h
2.032 L/24 h
140 mL/min
26.0 mL/min
30.2 mL/min
1512 mL/h
0.590

NaPost −NaPre ×(1−NaAR)
NaAR

124−118×(1−0.590)
0.590

128.2 mEq/L

NaRF − NaPre

128.2 − 118
for t = 1440
118 + 10.2 × (NaAR)
118 + 10.2 × (0.590)
118 × 42
V0 = L and QUF = L/h
124 × (42 − 0.0847 ×
24) − 118 × 42

10.2 mEq/L
124 mEq/L

)
(
D ∙t
− Na
NaPre + ∇Na × 1 − e V0
NaPre ⋅ V0
(
)
PNa (t) ⋅ V0 − QUF ⋅ t − NaPre ⋅ V0

4956 mEq
0 mEq

Table 3  CVVH parameters for treatment time from 24 to 48 h, using case example
Parameter

Equation

Urea reduction ratio (URR, percent as a fraction)
Urea clearance (KUrea, mL/min)

Specified variable

BUN Post ( BUNtx, mg/dL)

−V 0 ×LN(1−URR)
1440
K
∙tx
− Urea
BUN 0 × e V0

(NaPost, mEq/L)
Ultrafiltration rate that achieves zero sodium balance (QUF, mL/
min)

NaPre + 6 mEq/L
V0 ×(NaPost −NaPre )

Plasma flow ( QP, mL/min)
Sodium dialysance ( DNa, mL/min)
Replacement fluid flow rate ( QRF, mL/min)

QB × (1 – Hct)
DNa ≈ KUrea
QP ×(QUF −DNa )
(DNa −QP )

Sodium reduction ratio (NaAR, percent as a fraction)

NaPost ∙tx

−

1−e

DNa ∙tx
V0

Replacement fluid sodium concentration (NaRF, mEq/L)

Napost −NaPre ×(1−NaAR)

Sodium gradient (∇Na, mEq/L)
Plasma sodium concentration at time (t, min) during treatment
(PNa(t), mEq/L)

NaRF − NaPre

Total body Na (TBNa, mEq)
Change in total body Na at time (t) ΔTBNa(t), mEq)

NaPre ⋅ V0
(
)
PNa (t) ⋅ V0 − QUF ⋅ t − NaPre ⋅ V0

NaAR

)
(
D ∙t
− Na
NaPre + ∇Na × 1 − e V0

Calculation
−40000×LN(1−0.40)
1440
− 14.19×1440
40000

37.7 × e

124 + 6
40000×(130−124)
130×1440

200 × (1 − 0.30)
140×(1.28−14.19)
14.19−140

1 − e−

14.19×1440
40000

Value
0.40
14.19 mL/min
>23.2 mg/dL
130 mEq/L
1.28 mL/min
0.077 L/h
1.85 L/24 h
140 mL/min
14.19 mL/min
14.37 mL/min
861.8 mL/h
0.400

130−124×(1−0.40)
0.400

139 mEq/L

139 − 124
for t = 1440
124 + 15 × (NaAR)
124 + 15 × (0.400)
124 × 40
V0 = L and QUF = L/h
130 × (40 − 0.077 × 24)
− 124 × 40

15 mEq/L
130 mEq/L
4960 mEq
0 mEq
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Table 4  Day 2 treatment parameters
Parameter

Admission

Day 1

Day 2

Weight, kg
PNa, mEq/L
TBW, L
TBNa, mEq
Ultrafiltration, mL/h
Net change of TBNa, mEq

78
118
42
4956
0
0

75
124
39
4836
125
−122

72
130
36.2
4706
118
−252

the first treatment. Therefore, ΔTBNa equals 0 for the 48 h
of treatment, and volume overloading does not occur. Thus,
targeting net fluid loss with simultaneous correction of PNa
and no sodium gain is the desired treatment goal in the setting
of ADHF, hyponatremia, fluid overload, and increased TBNa.

Troubleshooting
Baseline (t = 0 min) and 2–4-hourly lab monitoring that
includes plasma sodium, potassium, chloride, total carbon
dioxide, blood urea nitrogen, creatinine, and glucose concentrations is recommended to evaluate the efficacy of SBO. A
failure of P
 Na to increase within 4 h requires reexamination
of calculations and checking equipment and the extracorporeal circuit for proper functioning. For example, inaccurately
low determination of N
 aRF will prevent elevation of P
 Na.
Accurate calculation of TBW at the beginning of therapy
is important because underestimating TBW results reduces
the rate of rise of PNa. If this occurs, increasing QP, QRF,
and increasing the sodium concentration gradient between
plasma and replacement fluid will increase PNa at a more
rapid rate. Rapid increases of P
 Na, (e.g., > 1 mmol/L per hour
for 4–6 hours) are rectified by decreasing QP, and QRF and
decreasing the sodium gradient between PNa and RF [68].

Achieving net negative sodium and fluid
balance
Applying the above equations while establishing a goal of
net negative fluid balance prevents the inevitable increase
of TBNa that accompanies P
 Na elevation. In our example,
TBNa excess is averted by increasing ultrafiltration by 1 L
per day. This maneuver produces a cumulative loss of 6 L
of fluid and PNa of 130 mEq/L after 48 h. An additional 1 L
of ultrafiltration volume removes an additional 122 mEq on
day 1 of treatment. The additional removal of 1 L of ultrafiltrate on day 2 removes an additional 130 mEq of sodium,
and a net sodium loss of 252 mEq is realized. The changes
of TBNa and PNa(t) are tabulated (Table 4).
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Predilution CVVH-SBO therapy controls the rate of urea
removal and the rate of increase (or decrease) of P
 Na. SBO
modeling provides an advantage for the treatment of hyponatremia in patients with oligoanuric ADHF. Implementation
of CVVH-SBO provides simple and smooth regulation of
TBNa through judicious determination of ultrafiltration.
When properly implemented, predilution CVVH-SBO
alleviates the congestion and corrects the hyponatremia of
ADHF in a safe and controlled fashion.

Disclosures
All authors have no relevant disclosures.
Acknowledgements The authors express their gratitude to Karla Passalacqua, PhD for her insightful reading of the manuscript.

References
1. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De
Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A,
Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela
B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott
MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL,
Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, WasserthielSmoller S, Wong ND, Wylie-Rosett J (2010) Heart disease and
stroke statistics–2010 update: a report from the American Heart
Association. Circulation 121:e46–e215. https://doi.org/10.1161/
circulationaha.109.192667
2. Voigt J, Sasha John M, Taylor A, Krucoff M, Reynolds MR,
Michael Gibson C (2014) A reevaluation of the costs of heart
failure and its implications for allocation of health resources in
the United States. Clin Cardiol 37:312–321. https://doi.org/10.
1002/clc.22260
3. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo
MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP (2005)
Characteristics and outcomes of patients hospitalized for heart
failure in the United States: rationale, design, and preliminary
observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart
J 149:209–216. https://doi.org/10.1016/j.ahj.2004.08.005
4. Gheorghiade M, Filippatos G (2005) Reassessing treatment of
acute heart failure syndromes: the ADHERE Registry. European
Heart Journal Supplements 7:B13–B19. https://doi.org/10.1093/
eurheartj/sui008
5. Jain P, Massie BM, Gattis WA, Klein L, Gheorghiade M (2003)
Current medical treatment for the exacerbation of chronic heart
failure resulting in hospitalization. Am Heart J 145:S3-17.
https://doi.org/10.1067/mhj.2003.149
6. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH,
Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR,
Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV,
Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang
WHW, Tsai EJ, Wilkoff BL (2013) 2013 ACCF/AHA guideline
for the management of heart failure. Circulation 128:e240-e327.
https://doi.org/10.1161/CIR.0b013e31829e8776
7. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE,
Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH,

Heart Failure Reviews

8.

9.
10.

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

Goldman S, Cobb FR, Shah PM, Saunders R, Fletcher RD, Loeb
HS, Hughes VC, Baker B (1986) Effect of vasodilator therapy
on mortality in chronic congestive heart failure. N Engl J Med
314:1547–1552. https://doi.org/10.1056/nejm198606123142404
Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier
RW, Sterns RH, Thompson CJ (2013) Diagnosis, evaluation, and
treatment of hyponatremia: expert panel recommendations. Am J
Med 126:S1-42. https://doi.org/10.1016/j.amjmed.2013.07.006
Upadhyay A, Jaber BL, Madias NE (2009) Epidemiology of
hyponatremia. Seminars in Nephrology 29:227–238. https://doi.
org/10.1016/j.semnephrol.2009.03.004
Balling L, Schou M, Videbæk L, Hildebrandt P, Wiggers H,
Gustafsson F, Network ftDHFC, (2011) Prevalence and prognostic significance of hyponatraemia in outpatients with chronic
heart failure. Eur J Heart Fail 13:968–973. https://doi.org/10.
1093/eurjhf/hfr086
Kearney MT, Fox KA, Lee AJ, Prescott RJ, Shah AM, Batin PD,
Baig W, Lindsay S, Callahan TS, Shell WE, Eckberg DL, Zaman
AG, Williams S, Neilson JM, Nolan J (2002) Predicting death
due to progressive heart failure in patients with mild-to-moderate
chronic heart failure. J Am Coll Cardiol 40:1801–1808. https://
doi.org/10.1016/s0735-1097(02)02490-7
Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Piña
IL, Fonarow GC, DeMarco T, Pauly DF, Rogers J, DiSalvo TG,
Butler J, Hare JM, Francis GS, Stough WG, O’Connor CM (2007)
Characterization and prognostic value of persistent hyponatremia
in patients with severe heart failure in the ESCAPE Trial. Arch
Intern Med 167:1998–2005. https://doi.o rg/10.1001/archin te.1 67.
18.1998
Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet
D, Decaux G, Fenske W, Hoorn EJ, Ichai C, Joannidis M, Soupart
A, Zietse R, Haller M, van der Veer S, Van Biesen W, Nagler E,
Group obotHGD (2014) Clinical practice guideline on diagnosis
and treatment of hyponatraemia. Nephrol Dial Transplant 29:i1–
i39. https://doi.org/10.1093/ndt/gfu040
Wang J, Zhou W, Yin X (2019) Improvement of hyponatremia is
associated with lower mortality risk in patients with acute decompensated heart failure: a meta-analysis of cohort studies. Heart
Fail Rev 24:209–217. https://d oi.o rg/1 0.1 007/s 10741-0 18-9 753-5
Qureshi W, Hassan S, Khalid F, Almahmoud MF, Shah B,
Tashman R, Ambulgekar N, El-Refai M, Mittal C, Alirhayim
Z (2013) Outcomes of correcting hyponatremia in patients with
myocardial infarction. Clinical research in cardiology : official
journal of the German Cardiac Society 102:637–644. https://doi.
org/10.1007/s00392-013-0576-z
Madan VD, Novak E, Rich MW (2011) Impact of change in serum
sodium concentration on mortality in patients hospitalized with
heart failure and hyponatremia. Circ Heart Fail 4:637–643. https://
doi.org/10.1161/circheartfailure.111.961011
Dunlap ME, Hauptman PJ, Amin AN, Chase SL, Chiodo JA, 3rd
Chiong JR, Dasta JF (2017) Current management of hyponatremia in acute heart failure: a report from the hyponatremia registry for patients with euvolemic and hypervolemic hyponatremia
(HN Registry) J Am Heart Assoc 6 https://doi.org/10.1161/jaha.
116.005261
Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran
JR, Wynne J (2007) High prevalence of renal dysfunction and its
impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail
13:422–430. https://doi.org/10.1016/j.cardfail.2007.03.011
Bibbins-Domingo K, Lin F, Vittinghoff E, Barrett-Connor E, Grady
D, Shlipak MG (2004) Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol
44:1593–1600. https://doi.org/10.1016/j.jacc.2004.07.040
Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM,
Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young

21.

22.
23.
24.
25.

26.

27.
28.

29.

30.

31.

32.
33.

34.
35.

36.
37.

JB, Krumholz HM (2004) Incidence, predictors at admission, and
impact of worsening renal function among patients hospitalized
with heart failure. J Am Coll Cardiol 43:61–67. https://doi.org/
10.1016/j.jacc.2003.07.031
Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho
B, Investigators obotP, (2006) Prevalence and impact of worsening renal function in patients hospitalized with decompensated
heart failure: results of the prospective outcomes study in heart
failure (POSH). Eur Heart J 27:1216–1222. https://doi.org/10.
1093/eurheartj/ehi859
Alcázar AR (2008) [Electrolyte and acid-base balance disorders in
advanced chronic kidney disease]. Nefrologia : publicacion oficial
de la Sociedad Espanola Nefrologia 28 Suppl 3:87–93
Schrier RW, Abraham WT (1999) Hormones and hemodynamics
in heart failure. N Engl J Med 341:577–585. https://doi.org/10.
1056/nejm199908193410806
Soi V, Yee J (2017) Sodium homeostasis in chronic kidney disease. Adv Chronic Kidney Dis 24:325–331. https://doi.org/10.
1053/j.ackd.2017.08.001
Rogerson FM, Chai SY, Schlawe I, Murray WK, Marley PD,
Mendelsohn FA (1992) Presence of angiotensin converting
enzyme in the adventitia of large blood vessels. J Hypertens
10:615–620
McDonough AA (2010) Mechanisms of proximal tubule sodium
transport regulation that link extracellular fluid volume and blood
pressure. Am J Physiol Regul Integr Comp Physiol 298:R851-861.
https://doi.org/10.1152/ajpregu.00002.2010
Schrier RW, Berl T, Anderson RJ (1979) Osmotic and nonosmotic
control of vasopressin release. Am J Physiol Ren Physiol 236:F321–
F332. https://doi.org/10.1152/ajprenal.1979.236.4.F321
Andersen LJ, Andersen JL, Schutten HJ, Warberg J, Bie P (1990)
Antidiuretic effect of subnormal levels of arginine vasopressin
in normal humans. Am J Physiol Regul Integr Comp Physiol
259:R53–R60. https://doi.org/10.1152/ajpregu.1990.259.1.R53
Dunn FL, Brennan TJ, Nelson AE, Robertson GL (1973) The
role of blood osmolality and volume in regulating vasopressin
secretion in the rat. J Clin Invest 52:3212–3219. https://doi.org/
10.1172/jci107521
Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN
(1983) Increased plasma arginine vasopressin levels in patients
with congestive heart failure. J Am Coll Cardiol 1:1385–1390.
https://doi.org/10.1016/s0735-1097(83)80040-0
Szatalowicz VL, Arnold PE, Chaimovitz C, Bichet D, Berl
T, Schrier RW (1981) Radioimmunoassay of plasma arginine
vasopressin in hyponatremic patients with congestive heart
failure. N Engl J Med 305:263–266. https://doi.org/10.1056/
nejm198107303050506
Ishikawa SE (2015) Hyponatremia associated with heart failure:
pathological role of vasopressin-dependent impaired water excretion. J Clin Med 4:933–947. https://doi.org/10.3390/jcm4050933
Bankir L (2001) Antidiuretic action of vasopressin: quantitative
aspects and interaction between V1a and V2 receptor-mediated
effects. Cardiovasc Res 51:372–390. https://doi.org/10.1016/
s0008-6363(01)00328-5
Jamison RL, Oliver RE (1982) Disorders of urinary concentration and dilution. Am J Med 72:308–322. https://d oi.o rg/1 0.1 016/
0002-9343(82)90823-3
Verbrugge FH, Steels P, Grieten L, Nijst P, Tang WHW, Mullens
W (2015) Hyponatremia in acute decompensated heart failure:
depletion versus dilution. Journal of the American College of Cardiology 65:480–492. https://doi.org/10.1016/j.jacc.2014.12.010
Shah SR, Bhave G (2018) Using electrolyte free water balance to
rationalize and treat dysnatremias. Front Med (Lausanne) 5:103.
https://doi.org/10.3389/fmed.2018.00103
Testani JM, Brisco MA, Turner JM, Spatz ES, Bellumkonda L,
Parikh CR, Tang WH (2014) Loop diuretic efficiency: a metric

13

Heart Failure Reviews

38.

39.

40.

41.

42.
43.
44.

45.

46.
47.

48.

49.

50.
51.

52.

of diuretic responsiveness with prognostic importance in acute
decompensated heart failure. Circ Heart Fail 7:261–270. https://
doi.org/10.1161/circheartfailure.113.000895
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni
AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer
C, Orlandi C (2007) Effects of oral tolvaptan in patients hospitalized
for worsening heart failure: the EVEREST Outcome Trial. JAMA
297:1319–1331. https://doi.org/10.1001/jama.297.12.1319
Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV,
Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, Gordon P,
Korr K, Fileccia R, Pressler SJ, Gregory D, Wedge P, Dowling
D, Romeling M, Konstam JM, Massaro JM, Udelson JE (2017)
Short-term effects of tolvaptan in patients with acute heart failure
and volume overload. J Am Coll Cardiol 69:1409–1419. https://
doi.org/10.1016/j.jacc.2016.12.035
Licata G, Di Pasquale P, Parrinello G, Cardinale A, Scandurra A,
Follone G, Argano C, Tuttolomondo A, Paterna S (2003) Effects
of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as
bolus in refractory congestive heart failure: long-term effects. Am
Heart J 145:459–466. https://doi.org/10.1067/mhj.2003.166
Gandhi S, Mosleh W, Myers RB (2014) Hypertonic saline with
furosemide for the treatment of acute congestive heart failure: a
systematic review and meta-analysis. Int J Cardiol 173:139–145.
https://doi.org/10.1016/j.ijcard.2014.03.020
Strange K (2004) Cellular volume homeostasis. Adv Physiol Educ
28:155–159. https://doi.org/10.1152/advan.00034.2004
Verbalis JG (2010) Brain volume regulation in response to
changes in osmolality. Neuroscience 168:862–870. https://doi.
org/10.1016/j.neuroscience.2010.03.042
Edelman IS, Leibman J, O’Meara MP, Birkenfeld LW (1958)
Interrelations between serum sodium concentration, serum osmolarity and total exchangeable sodium, total exchangeable potassium and total body water. J Clin Investig 37:1236–1256. https://
doi.org/10.1172/JCI103712
Watson PE, Watson ID, Batt RD (1980) Total body water volumes
for adult males and females estimated from simple anthropometric
measurements. Am J Clin Nutr 33:27–39. https://d oi.o rg/1 0.1 093/
ajcn/33.1.27
Titze J (2013) Interstitial fluid homeostasis and pressure: news
from the black box. Kidney International 84:869–871. https://doi.
org/10.1038/ki.2013.287
Reed RK, Rubin K, Wiig H, Rodt SA (1992) Blockade of beta
1-integrins in skin causes edema through lowering of interstitial
fluid pressure. Circulation Research 71:978–983. https://doi.org/
10.1161/01.RES.71.4.978
Nijst P, Verbrugge FH, Grieten L, Dupont M, Steels P, Tang
WHW, Mullens W (2015) The pathophysiological role of interstitial sodium in heart failure. Journal of the American College of
Cardiology 65:378–388. https://d oi.o rg/1 0.1 016/j.j acc.2 014.1 1.0 25
Wiig H, Luft FC, Titze JM (2018) The interstitium conducts
extrarenal storage of sodium and represents a third compartment
essential for extracellular volume and blood pressure homeostasis
Acta Physiol (Oxf) 222 https://doi.org/10.1111/apha.13006
Titze J (2014) Sodium balance is not just a renal affair. Curr
Opin Nephrol Hypertens 23:101–105. https://doi.org/10.1097/
01.mnh.0000441151.55320.c3
Kopp C, Linz P, Wachsmuth L, Dahlmann A, Horbach T, Schöfl
C, Renz W, Santoro D, Niendorf T, Müller DN, Neininger M,
Cavallaro A, Eckardt KU, Schmieder RE, Luft FC, Uder M,
Titze J (2012) (23)Na magnetic resonance imaging of tissue
sodium. Hypertension (Dallas, Tex : 1979) 59:167–172. https://
doi.org/10.1161/hypertensionaha.111.183517
Hammon M, Grossmann S, Linz P, Kopp C, Dahlmann A,
Garlichs C, Janka R, Cavallaro A, Luft FC, Uder M, Titze J
(2015) 23Na magnetic resonance imaging of the lower leg of

13

53.

54.

55.

56.

57.
58.

59.

60.

61.

62.
63.
64.

65.

66.

acute heart failure patients during diuretic treatment. PLoS ONE
10:e0141336. https://doi.org/10.1371/journal.pone.0141336
Dahlmann A, Dörfelt K, Eicher F, Linz P, Kopp C, Mössinger I,
Horn S, Büschges-Seraphin B, Wabel P, Hammon M, Cavallaro
A, Eckardt KU, Kotanko P, Levin NW, Johannes B, Uder M, Luft
FC, Müller DN, Titze JM (2015) Magnetic resonance-determined
sodium removal from tissue stores in hemodialysis patients. Kidney Int 87:434–441. https://doi.org/10.1038/ki.2014.269
Shattock MJ, Ottolia M, Bers DM, Blaustein MP, Boguslavskyi A,
Bossuyt J, Bridge JH, Chen-Izu Y, Clancy CE, Edwards A, Goldhaber
J, Kaplan J, Lingrel JB, Pavlovic D, Philipson K, Sipido KR, Xie
ZJ (2015) Na+/Ca2+ exchange and Na+/K+-ATPase in the heart. J
Physiol 593:1361–1382. https://doi.org/10.1113/jphysiol.2014.282319
McCarroll CS, He W, Foote K, Bradley A, McGlynn K, Vidler F,
Nixon C, Nather K, Fattah C, Riddell A, Bowman P, Elliott EB, Bell
M, Hawksby C, MacKenzie SM, Morrison LJ, Terry A, Blyth K,
Smith GL, McBride MW, Kubin T, Braun T, Nicklin SA, Cameron
ER, Loughrey CM (2018) Runx1 deficiency protects against adverse
cardiac remodeling after myocardial infarction. Circulation 137:57–
70. https://doi.org/10.1161/circulationaha.117.028911
Tse G, Yeo JM (2015) Conduction abnormalities and ventricular
arrhythmogenesis: The roles of sodium channels and gap junctions. International journal of cardiology Heart & vasculature
9:75–82. https://doi.org/10.1016/j.ijcha.2015.10.003
Movafagh S, Cleemann L, Morad M (2011) Regulation of cardiac
Ca(2+) channel by extracellular Na(+). Cell Calcium 49:162–173.
https://doi.org/10.1016/j.ceca.2011.01.008
Ramsaroop K, Seecheran R, Seecheran V, Persad S, Giddings S,
Mohammed B, Seecheran NA (2019) Suspected hyponatremiainduced Brugada phenocopy. International medical case reports
journal 12:61–65. https://doi.org/10.2147/imcrj.S200201
Can Ç, Gulacti U, Kurtoglu E, Celik A, Lok U, Topacoglu H
(2014) The relationship between serum sodium concentration and
atrial fibrillation among adult patients in emergency department
settings. Akademik Acil T?p Dergisi 13:131–134. https://doi.org/
10.5152/jaem.2014.172
A Pavlikova A Shevelyok N Vatutin (2020) P1395 The role of
hyponatremia in the development of atrial fibrillation after cardiac
surgery EP Europace 22 https://doi.org/10.1093/europace/e uaa16 2.
058
Cavusoglu Y, Kaya H, Eraslan S, Yilmaz MB (2019) Hyponatremia is associated with occurrence of atrial fibrillation in outpatients with heart failure and reduced ejection fraction. Hellenic
journal of cardiology : HJC = Hellenike kardiologike epitheorese
60:117–121. https://doi.org/10.1016/j.hjc.2018.03.006
Kottwitz J, Akdis D, Duru F, Heidecker B (2016) severe hyponatremia leading to complete atrioventricular block. Am J Med
129:e243–e244. https://doi.org/10.1016/j.amjmed.2016.05.033
Hoorn EJ, Zietse R (2017) Diagnosis and treatment of hyponatremia: compilation of the guidelines. J Am Soc Nephrol 28:1340–
1349. https://doi.org/10.1681/ASN.2016101139
De Vecchis R, Noutsias M, Ariano C, Cesaro A, Cioppa C, Giasi
A, Maurea N (2017) Does Accidental overcorrection of symptomatic hyponatremia in chronic heart failure require specific therapeutic adjustments for preventing central pontine myelinolysis?
Journal of clinical medicine research 9:266–272. https://doi.org/
10.14740/jocmr2933w
Neyra JA, Yessayan L, Thompson Bastin ML, Wille K, Tolwani
AJ (2020) How to prescribe and troubleshoot continuous renal
replacement therapy: a case-based review. Kidney360: https://d oi.
org/10.34067/KID.0004912020
Hamdi T, Yessayan L, Yee J, Szamosfalvi B (2018) High sodium
continuous veno-venous hemodialysis with regional citrate anticoagulation and online dialysate generation in patients with acute
liver failure and cerebral edema. Hemodial Int 22:184–191.
https://doi.org/10.1111/hdi.12572

Heart Failure Reviews
67. Yee J, Mohiuddin N, Gradinariu T, Uduman J, Frinak S (2020)
Sodium-based osmotherapy in continuous renal replacement therapy: a mathematical approach. Kidney360 1:281–291. https://doi.
org/10.34067/kid.0000382019
68. Yee J, Mohiuddin N, Gradinariu T, Uduman J, Frinak S (2020)
Sodium-based osmotherapy in continuous renal replacement
therapy: a mathematical approach. Kidney360 1:281. https://doi.
org/10.34067/KID.0000382019
69. Chawla LS, Davison DL, Brasha-Mitchell E, Koyner JL, Arthur
JM, Shaw AD, Tumlin JA, Trevino SA, Kimmel PL, Seneff MG
(2013) Development and standardization of a furosemide stress
test to predict the severity of acute kidney injury. Crit Care
17:R207–R207. https://doi.org/10.1186/cc13015
70. Kwok CS, Wong CW, Rushton CA, Ahmed F, Cunnington C,
Davies SJ, Patwala A, Mamas MA, Satchithananda D (2017)
Ultrafiltration for acute decompensated cardiac failure: A systematic review and meta-analysis. International Journal of Cardiology
228:122–128. https://doi.org/10.1016/j.ijcard.2016.11.136
71. Singh TD, Fugate JE, Rabinstein AA (2014) Central pontine
and extrapontine myelinolysis: a systematic review. Eur J Neurol
21:1443–1450. https://doi.org/10.1111/ene.12571

72. Tolwani AJ, Campbell RC, Stofan BS, Lai KR, Oster RA, Wille
KM (2008) Standard versus high-dose CVVHDF for ICU-related
acute renal failure. J Am Soc Nephrol 19:1233–1238. https://doi.
org/10.1681/asn.2007111173
73. Karkar A, Ronco C (2020) Prescription of CRRT: a pathway to
optimize therapy. Ann Intensive Care 10:32. https://doi.org/10.
1186/s13613-020-0648-y
74. Polaschegg HD (1993) Automatic, noninvasive intradialytic clearance measurement. The International journal of artificial organs
16:185–191
75. Steil H, Kaufman AM, Morris AT, Levin NW, Polaschegg HD
(1993) In vivo verification of an automatic noninvasive system
for real time Kt evaluation. ASAIO journal (American Society
for Artificial Internal Organs : 1992) 39:M348–352
Publisher’s Note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.

13

